GFM
AVXL icon

GF Fund Management’s Anavex Life Sciences AVXL Stock Holding History

GF Fund Management’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.09K Sell
1,964
-30
-2% -$89 ﹤0.01% 570
2026
Q1 		$6.12K Buy
1,994
+239
+14% +$1.03K ﹤0.01% 595
2025
Q4 		$6.25K Sell
1,755
-93
-5% -$570 ﹤0.01% 609
2025
Q3 		$16.4K Sell
1,848
-323
-15% -$3.28K ﹤0.01% 512
2025
Q2 		$20K Hold
2,171
– – ﹤0.01% 505
2025
Q1 		$18.6K Buy
2,171
+391
+22% +$3.69K ﹤0.01% 509
2024
Q4 		$19.1K Buy
+1,780
New +$13.7K ﹤0.01% 475

Other funds holding AVXL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SF
Summit Financial Parsippany, New Jersey $9.12B AUM 27.44% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

GF Fund Management's AVXL Position: Q2 2026 in Review

GF Fund Management reduced its Anavex Life Sciences (AVXL) stake by 1.5% in Q2 2026, selling an estimated $89 and leaving 1,964 shares worth $5.09K. The position accounts for ﹤0.01% of the portfolio, ranked #570.

GF Fund Management first reported a position in AVXL in Q4 2024 and has held it in 7 quarters since. The position peaked at $20K in Q2 2025. 179 funds tracked by Wall St. Rank hold AVXL as of Q2 2026.

  • GF Fund Management held 1,964 shares of Anavex Life Sciences worth $5.09K as of Q2 2026.
  • GF Fund Management sold 30 Anavex Life Sciences shares in Q2 2026, an estimated $89.
  • Anavex Life Sciences made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #570 holding.
  • GF Fund Management first reported a position in Anavex Life Sciences in Q4 2024 and has held it in 7 quarters since.
  • GF Fund Management's Anavex Life Sciences position peaked at $20K in Q2 2025.
  • 179 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.